Acumen Pharmaceuticals (ABOS) Projected to Post Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.39) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 12:30 PM ET.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. On average, analysts expect Acumen Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acumen Pharmaceuticals Stock Up 1.1%

NASDAQ:ABOS traded up $0.03 during trading hours on Tuesday, hitting $2.21. The stock had a trading volume of 128,851 shares, compared to its average volume of 608,053. The company has a market cap of $159.27 million, a PE ratio of -1.19 and a beta of 0.36. The business has a 50 day simple moving average of $2.38 and a two-hundred day simple moving average of $2.52. Acumen Pharmaceuticals has a 1-year low of $1.19 and a 1-year high of $3.60. The company has a current ratio of 4.55, a quick ratio of 4.55 and a debt-to-equity ratio of 0.19.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ABOS shares. Wall Street Zen downgraded shares of Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.00.

Insider Activity

In other Acumen Pharmaceuticals news, Director Derrell Porter sold 13,040 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $2.33, for a total transaction of $30,383.20. Following the completion of the transaction, the director directly owned 35,500 shares of the company’s stock, valued at $82,715. This trade represents a 26.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 38,700 shares of company stock valued at $89,660 in the last three months. 10.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. bought a new stake in Acumen Pharmaceuticals in the third quarter valued at about $27,000. Marshall Wace LLP acquired a new position in shares of Acumen Pharmaceuticals in the 4th quarter worth approximately $44,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Acumen Pharmaceuticals in the 4th quarter valued at approximately $47,000. Marex Group plc acquired a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter valued at approximately $39,000. Finally, AQR Capital Management LLC bought a new position in Acumen Pharmaceuticals during the first quarter worth $46,000. 71.01% of the stock is currently owned by institutional investors and hedge funds.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.